EUVIMEDОткрийте EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY 4.0

Vitamin D supplementation in the first 2 years and autism spectrum traits at 6–8 years – a randomized clinical trial

Samuel Sandboge iD, Vilja Seppälä, Sakari Lintula, Elisa Holmlund-Suila, Helena Hauta-Alus, Eero Kajantie, Outi Mäkitie, Sture Andersson, Katri Räikkönen, Kati Heinonen iD

Journal of Child Psychology and Psychiatry · 2026-07 · 67 (7) · 1004-1014

DOI: 10.1111/jcpp.70110 ↗

At a glance

Randomisierte kontrollierte Studie in Journal of Child Psychology and Psychiatry, published online on 2026-01-05. Written by Samuel Sandboge and 9 co-authors. Institution: Psychology/Welfare Sciences, Faculty of Social Sciences, University of Tampere, Tampere, Finland. Major MEDLINE topics: Autism Spectrum Disorder, Vitamin D, Dietary Supplements, Cholecalciferol. 56 references. The full text is freely available (open access, CC BY 4.0). Funded by: Suomen Lääketieteen Säätiö, Academy of Finland, Sigrid Juséliuksen Säätiö.

РезюмеSubjectsБиблиографски данниCiteRelated studies

Abstract (original language)

Background

Early life vitamin D levels may be associated with autism spectrum disorder (ASD) and related traits, but causality is unknown. We examine whether higher‐than‐standard vitamin D 3 supplementation during the first 2 years, as well as higher pregnancy and childhood 25‐hydroxyvitamin D (25(OH)D) levels and their trajectories, are associated with lower ASD trait scores at ages 6–8 years in a non‐clinical cohort.

Methods

This secondary analysis of the double‐blind randomized clinical trial vitamin D intervention in infants (VIDI) comprised 366 Finnish children aged 6–8 years, 177 of whom were randomized to receive 400‐IU and 189 to receive 1,200‐IU daily oral vitamin D 3 supplementation between ages 2 weeks and 2 years. ASD‐related traits were assessed at mean age 7.2 years (SD 0.4) using the parent‐reported Autism Spectrum Screening Questionnaire (ASSQ). Predictor variables were supplementation group, 25(OH)D concentrations measured during pregnancy and at ages 1 and 2 years, as well as 25(OH)D trajectories (high vs. low) derived from these time points.

Results

None of the predictor variables of interest were associated with the outcome in the full sample. After sex stratification, among boys, 25(OH)D concentrations at 1 and 2 years were inversely associated with ASSQ scores (mean difference −0.2 of normalized SD score (95% CI −0.3 to −0.1, p = .003) and −0.2 (95% CI −0.3 to −0.05, p = .01) per 10 ng/mL 25(OH)D) after adjustment for age, breastfeeding, parental education, maternal depressive symptoms, and season of 25(OH)D assessment as was belonging to the higher 25(OH)D trajectory, −0.45 SD (95% CI −0.79 to −0.10, p = .01).

Conclusions

We found no indication that higher‐than‐normal vitamin D 3 supplementation between ages 0 and 2 years decreases ASD‐related trait scores at ages 6–8 years. Sex‐stratified analysis suggested an inverse association, among boys, between early life 25(OH)D concentrations and ASD‐related traits, warranting further studies on potential causal direction and sex specificity of associations.

Subjects

MeSH terms (MEDLINE)

Autism Spectrum DisorderVitamin DDietary SupplementsCholecalciferolVitaminsHumansFemaleChildMaleDouble-Blind MethodChild, PreschoolFinlandInfantPregnancyInfant, Newborn

Author keywords

Vitamin Dautism spectrum disorderneurodevelopmentrandomized clinical trial

Substances

Vitamin D25-hydroxyvitamin DCholecalciferolVitamins

Authors and institutions

  • Psychology/Welfare Sciences, Faculty of Social Sciences, University of Tampere, Tampere, Finland.
  • Population Health Unit, Finnish Institute for Health and Welfare, Helsinki and Oulu, Finland.
  • Department of Psychology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • HUS Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Children's Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Research Program for Clinical and Molecular Metabolism (CAMM), Faculty of Medicine, University of Helsinki, Helsinki, Finland.

ORCID profiles: Samuel Sandboge, Kati Heinonen

Funding

  • Suomen Lääketieteen Säätiö
  • Academy of Finland
  • Sigrid Juséliuksen Säätiö
  • Signe ja Ane Gyllenbergin Säätiö
  • Lastentautien Tutkimussäätiö
  • Yrjö Jahnssonin Säätiö
  • Novo Nordisk Fonden
  • Finska Läkaresällskapet

Cite

APA

Sandboge, S., Seppälä, V., Lintula, S., Holmlund-Suila, E., Hauta-Alus, H., Kajantie, E., Mäkitie, O., Andersson, S., Räikkönen, K., & Heinonen, K. (2026). Vitamin D supplementation in the first 2 years and autism spectrum traits at 6–8 years – a randomized clinical trial. Journal of Child Psychology and Psychiatry, 67(7), 1004-1014. https://doi.org/10.1111/jcpp.70110

Vancouver

Sandboge S, Seppälä V, Lintula S, Holmlund-Suila E, Hauta-Alus H, Kajantie E, et al. Vitamin D supplementation in the first 2 years and autism spectrum traits at 6–8 years – a randomized clinical trial. Journal of Child Psychology and Psychiatry. 2026;67(7):1004-1014. doi:10.1111/jcpp.70110

BibTeX
@article{Sandboge2026,
  author = {Sandboge, Samuel and Seppälä, Vilja and Lintula, Sakari and Holmlund-Suila, Elisa and Hauta-Alus, Helena and Kajantie, Eero and Mäkitie, Outi and Andersson, Sture and Räikkönen, Katri and Heinonen, Kati},
  title = {Vitamin D supplementation in the first 2 years and autism spectrum traits at 6–8 years – a randomized clinical trial},
  journal = {Journal of Child Psychology and Psychiatry},
  year = {2026},
  volume = {67},
  number = {7},
  pages = {1004--1014},
  doi = {10.1111/jcpp.70110}
}
Start for free →